Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its position in Disc Medicine, Inc. (NASDAQ:IRON) by 38.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,560 shares of the company’s stock after acquiring an additional 5,458 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Disc Medicine were worth $961,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IRON. Frazier Life Sciences Management L.P. raised its holdings in shares of Disc Medicine by 123.5% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after purchasing an additional 969,834 shares in the last quarter. Logos Global Management LP purchased a new position in Disc Medicine in the second quarter valued at $41,690,000. Point72 Asset Management L.P. acquired a new stake in Disc Medicine in the second quarter valued at $34,318,000. Deerfield Management Company L.P. Series C lifted its holdings in Disc Medicine by 53.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock worth $46,119,000 after buying an additional 357,730 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Disc Medicine by 68.2% during the 3rd quarter. Janus Henderson Group PLC now owns 749,827 shares of the company’s stock worth $36,828,000 after acquiring an additional 303,954 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Insider Buying and Selling at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Jacob Savage sold 14,183 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $65.45, for a total transaction of $928,277.35. Following the transaction, the insider now owns 40,405 shares in the company, valued at approximately $2,644,507.25. This trade represents a 25.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,627 shares of company stock valued at $2,883,150 in the last ninety days. Insiders own 4.24% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IRON shares. Wedbush reissued an “outperform” rating and set a $83.00 target price on shares of Disc Medicine in a research report on Monday, December 9th. Jefferies Financial Group initiated coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective on the stock. Scotiabank boosted their price objective on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Stifel Nicolaus increased their target price on shares of Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Disc Medicine currently has an average rating of “Buy” and a consensus price target of $87.50.

Disc Medicine Price Performance

IRON stock opened at $63.50 on Thursday. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -15.95 and a beta of 0.76. The company has a fifty day moving average price of $58.19 and a 200 day moving average price of $50.24. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15. As a group, analysts anticipate that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.